. These data indicate that gravin is an inducible, cell type-specific cytoplasmic protein and that autoantibodies to gravin may be highly specific for MG. (J. Clin. Invest. 1992.90:992-999.)
Introduction
Myasthenia gravis (MG)' is a disease of neuromuscular transmission generally believed to be due to autoantibodies to the nicotinic acetylcholine receptor ( 1) . In addition, myasthenics also frequently form antibodies which react with striational muscle antigens (2-4), due to recognition of cytoskeletal elements such as alpha actinin, actin, filamin, and vinculin (5, 6) . Such cortical cytoskeletal elements localize (7) with acetylcholine receptors at motor endplates, and may be physically linked to the receptors. Since many regions ofthe acetylcholine receptor are antigenic targets for myasthenic sera ( 1) , it is unlikely that such antibodies arise by "molecular mimicry" (8) , i.e., that a restricted antigenic site on the receptor cross-reacts with an exogenous antigen. At present, the alternative hypothesis, that the response to the receptor is "antigen driven", is therefore favored ( 1). Thus, the autoantibodies present in myasthenic sera may serve to identify intracellular components that may link to transmembrane proteins.
Isolation of cDNA clones through their expressed antigenic sites (9-13) has been extensively used to isolate clones coding for autoantigens. This approach also offers the possibility of identifying and characterizing novel autoantigens that may be of low abundance and restricted cellular distribution ( 14) . Such proteins may escape detection by more routine screening tests such as immunofluorescence and immunoprecipitation.
We have used this approach to isolate cDNA clones that code for an apparently novel cytoplasmic antigen recognized by sera of some patients with MG. This antigen is present in a 250-kD cytoplasmic protein whose cellular distribution suggests that it is a component of the cortical cytoskeleton ( 15, 16) . Finally, the protein bearing this antigen and its mRNA are expressed in a cell type-specific and regulatable fashion by cells in culture.
Methods
Screening of cDNA librar' and protein blotting. Recombinant phage from a Xgt 11 human umbilical vein endothelial cDNA library (17) (generously provided by J. Evan Sadler, Washington University, St. Louis, MO) were plated on Escherichia coli strain Y 1090. overlaid with nitrocellulose filters (Millipore Corp., Bedford, MA), saturated with 10 mM isopropylthioglucose (IPTG) (Sigma Chemical Co., St. Louis, MO), and screened as described (18) with serum from a patient ( I ) with autoantibodies to both platelet glycoprotein lIla and to the acetylcholine receptor (19) . She is a 47-yr-old white woman with refractory idiopathic thrombocytopaenic purpura of 16 Bacterial lysates prepared from E. coli strain Y1089/phage lysogens induced with IPTG as described (18) were resolved on SDS polyacrylamide gels (20) and reactivity of the beta-galactosidase-cDNA fusion protein with human sera and rabbit antisera determined by immunoblotting nitrocellulose transfers (18) . Human -y and ,u chain-specific biotinylated second antibodies were used to determine the immunoglobulin class (Vector Laboratories, Inc., Burlingame, CA). CellsM saline, pH 7.4 (PBS), and lysed at ambient temperature in 1% Triton X-100 containing EDTA ( 10 mM) benzamidine ( 10 ;ig/ml) and Trasylol ( 100 U/ml). After centrifugation ( 16,000g, 30 min) supernatants were mixed with an equal volume of reducing sample buffer before resolution on SDS polyacrylamide gels (10) , electrophoretic transfer to nitrocellulose paper, and immunoblotting ( 18 Cell isolation and cell lines. Human platelets were isolated from acid citrate dextrose anticoagulated human blood by differential centrifugation followed by gel filtration (26) . Neutrophils were collected from freshly drawn venous blood by the method ofHenson and Oades (27) . PBMC were isolated from heparinized blood by centrifugation through Ficoll Hypaque (28) . Primary culture human umbilical vein endothelial cells (HUVE) were isolated and grown to confluence on 75-cm2 tissue culture flasks (29) and human promyeloid leukemic cell line U936 were cultured asdescribed (30 Recombinant antigen ELISAfor detection ofantigravin antibodies. The X15 insert was subcloned into the pQE-10 vector (Qiagen, Chatsworth, CA) and expressed as an in-frame fusion protein with six histidines at the NH2 terminus. Recombinant protein was purified under nondenaturing conditions by nickel chelate affinity chromatography using a pH 8-5 gradient (32) . Microwell ELISA plates (Nunc, Roskilde, Denmark) were coated with 150 ,u ofpurified recombinant protein at a concentration of 5 ,ug/ml in 0.03 M sodium carbonate, pH 9.6 at 4°C overnight, followed by blocking for 2 h with 3% BSA in PBS. The wells were then incubated for 90 min at 37°C with 0.1 ml duplicate serum samples diluted 1:250 which were preabsorbed with E. coli extract (Promega Corp., Madison, WI) to reduce background, washed four times with PBS-0.05% Tween 20, and incubated with 0.1 ml of a 1:1,000 anti-human IgG (Sigma Chemical Co., St. Louis, MO) for 2 h at 37°C. After four washes with PBS-Tween 0.1 ml of substrate (disodium p-nitrophenyl phosphate, Sigma Chemical Co.) dissolved in diethanolamine buffer (pH 9.8) was added to each well and the OD at 405 nm monitored using an ELISA plate reader (MR 600; Dynatech Laboratories, Inc., Chantilly, VA). The rabbit anti-X15 antiserum was used as a positive control in each experiment and the plates read when a 1:2,000 dilution reached an OD of -1.8. OD values greater than the mean +3 SD from 50 normal controls were considered positive.
Results
Isolation ofcDNA clones codingfor epitopes recognized by an MG serum. We isolated initial clones by screening a Xgtl 1 expression library constructed with cDNA complementary to mRNA isolated from cultured HUVE (17) with serum from patient 1. Initial screening of 500,000 recombinants yielded 10 immunoreactive clones. These clones did not react with polyclonal anti-GPIIb-IIIa antisera (30) , rabbit polyclonal antibody to the acetylcholine receptor, or with a panel of 25 sera from patients with chronic idiopathic thrombocytopaenic purpura. In addition, reactivity of the patient's serum with the fusion polypeptides remained after absorption with whole platelets, platelet membranes, and purified GPIIb-IIIa (not shown). This suggested that these cDNAs did not encode epitopes shared with platelet membrane proteins or the acetylcholine receptor. Antibodies affinity-purified from the patient's serum using the protein (25) from one clone containing a 2.0-kb insert, designated Xl 5, cross-reacted with 5:9 of the remaining cDNA clones. None of the cross-reactive clones reacted with pooled human IgG nor did 2:4 of the non-cross-reactive clones. The two clones reactive with pooled normal human IgG were not evaluated further. Sera obtained on three occasions between 1985 and 1987 from patient 1 were reactive with the X15 fusion protein on immunoblots as were multiple serum samples from a second patient with MG (2). A 32P-labeled RNA probe constructed with T3 RNA polymerase from the XI5cDNA after subcloning into Bluescript M1 3 cross-hybridized only with the immunologically related clones, indicating that the six clones shared overlapping cDNA sequence. On Western blotting, a single polypeptide of apparent Mr = 180,000 present in extracts ofE. coli Y 1089 infected (9) with phage bearing the Xi5 insert, but not wild type phage, reacted with the patient's serum (Fig. 1 ). This polypeptide reacted with Cell-type-specific expression ofgravin and gravin mRNA. Rabbit polyclonal antibodies against the X15 fusion polypeptide were prepared and used to characterize the cDNA-encoded protein. Rabbit polyclonal anti-X 15 immunoblotted an apparent M, 250,000 protein (designated gravin) in extracts of several preparations ofprimary cultures ofHUVE on reduced and nonreduced SDS gels. Faint bands of lower molecular weight were seen on some blots and were presumed to be proteolytic fragments. Reactivity with the 250-kD band was blocked by absorption ofpolyclonal serum with the X15 fusion protein and not observed with preimmune rabbit serum (Fig. 2) . Gravin was not detected in the spent culture media (not shown). Both prototype myasthenic sera (#1 and #2) also reacted with the 250-kD endothelial protein on immunoblots, confirming that the reactivity of patient sera with the insert-coded polypeptide was associated with reactivity with an endothelial cell protein which shared epitopes with the polypeptide encoded by Xl 5 (Fig. 2) . The Xl 5 insert hybridized with two mRNA species from HUVE on Northern blots (Fig. 3) . The size of these species ( -6.7 and 8.4 kb) could encode a polypeptide of the size of gravin. No mRNA hybridizing with Xl 5 was detected in blots from two cell lines which grow in suspension, HEL and U937, suggesting that expression of this protein might be celltype-specific. To explore this possibility, Western blots of a variety of cultured cell extracts were probed with the anti-X15 (Fig. 4) . Detection ofantigravin antibodies in patients with MG and other autoimmune diseases by recombinant antigen ELISA.
IgG autoantibodies to the recombinant gravin fragment were identified in 22:72 (31%) of MG sera and in 1: 17 patients with rheumatoid arthritis (> mean + 3 SD of 50 normal sera = 0.26 OD units). No reactivity was observed with normals or with sera from patients with systemic lupus erythematosus, progressive systemic sclerosis, chronic active hepatitis, and polymyositis (Fig. 6 ). Within this group were patients with known reactivities to the Ro, La, RNP, Sm, centromere, Scl-70, dsDNA, histone, and proliferating cell nuclear antigens. Prototype -Dg +Dg Absorbed Figure 5 . Immunofluorescent localization of gravin. Affinity-purified anti-XI5 antibody was used to stain detergent permeabilized cells (A) or intact cells (B). C shows staining of permeabilized cells with anti-X 15 which had been preabsorbed with the insert coded polypeptide (see Fig. 2 ). In the permeable cells note the meshwork staining which extends all the way to the cell periphery and into ruffles and filopodia. Note Figure 6 . Reactivity of human sera with X15 fusion protein by ELISA. Serum samples were tested in duplicate at a 1:250 dilution and OD read at 405 nm. Values above the horizontal line (mean + 3 SD from 50 normal subjects) were considered positive. MG, myasthenia gravis; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; PSS, progressive systemic sclerosis; CAH, chronic active hepatitis; PM, polymyositis. and band 4.1-related species (37) and talin (38) . In addition, an anti-chicken Fodrin common subunit reacted with a 235-kD species from brain cortex and HUVE, whereas anti-X15 reacted with neither. Finally, neither the anti-Fodrin, nor the anti-actin-binding protein reacted with the expressed insert coded polypeptide in Western blots (not shown). Thus we conclude that XI 5 does not encode epitopes recognized by these antibodies against either Fodrin or actin-binding protein.
Nucleotide andpredictedpeptide sequence ofthe X15 insert. The determined nucleotide and predicted peptide sequence of the X15 insert appear in Fig. 8 . The insert contains 1,993 bases terminating with the polyadenylation signal followed 15 bases downstream by 12 adenines, indicating that the insert is complementary to the 3' end of the mRNA. A long open reading frame, in frame with the linkers used in library construction ( 17) , coded for a 306 residue peptide which terminated with a TAA stop condon at nucleotide 920 and contained no predicted sites for Asn-linked oligosaccharides. The predicted molecular mass for this peptide was 33,056 D and it was moderately hydrophilic and strongly acidic, with a predicted net charge of -48. The predominant (39) predicted secondary structure within the peptide was alpha helix and numerous continuous antigenic sites were predicted by the algorithm of Jameson and Wolf (40) . Searches ofGenbank and EMBL nucleic acid databases and NBRF protein databases (as ofMarch, 1992) with the Wordsearch program did not reveal significant sequence identities. There was a weak similarity at the protein level to the carboxy terminus ofthe pig neurofilament triplet L protein (41 ) , and the similarity was judged significant using the Relate (42) rather than the actual predicted size of 33 kD. It should be noted that following nucleotide 920 there were multiple stop codons in all three reading frames. Moreover, previous work has drawn attention to the aberrant migration of highly acidic fusion proteins ( 10) Fig. 1 .
recent study has described reactivity with a 320-kD sarcoplasmic reticulum protein (43) . Antibodies to filamin and vinculin have been reported to occur in 97% and 30% of myasthenics, respectively (6) . Like gravin, titers of these antibodies do not correlate with anti-acetylcholine receptor antibody levels (6) . Detailed clinical studies will be necessary to determine the relationship, if any, of antigravin antibodies with the clinical features, thymic pathology, and course of MG. It seems likely that gravin is encoded by the cDNAs isolated here. First, polyclonal antibodies raised against recombinant fusion protein in two rabbits and antibodies affinity-purified on the fusion protein reacted with gravin on crude cell extracts, while reactivity was blocked by absorption of rabbit antisera with fusion protein. Second, serum from patients with myasthenia gravis reacted with both the insert-coded polypeptide and native 250-kD protein. Third, the mRNA species identified by Northern blotting with the cDNA is sufficient to encode a polypeptide the size of gravin. Fourth, the mRNa encoding the putative protein showed the same cell type-specific expression as gravin on Northern blots.
The meshwork staining of the cytoplasm and its peripheral extensions observed for gravin suggests that it is present in the cell cortex. It is noteworthy that several ofthe cytoskeletal proteins recognized by MG sera are components of the cortical cytoskeleton. Nevertheless, immunologic analysis indicates that gravin is distinct from actin binding protein (filamin) and nonerythroid spectrin (fodrin) which also localize to this region (34, 35 ) . Since MG does not, in most cases (1) , appear to be due to molecular mimicry, it has been suggested that the response is driven by antigens contained in the acetylcholine receptor and its associated cytoskeletal anchor. The site at which immunization occurs has not been definitely established, although the thymus (44) has been implicated. In view of the cell type-specific expression ofgravin, it may be of value
